Literature DB >> 21971021

Metabotropic glutamate antagonists alone and in combination with morphine: comparison across two models of acute pain and a model of persistent, inflammatory pain.

Mitchell J Picker1, Dana Daugherty, Fredrick E Henry, Laurence L Miller, Linda A Dykstra.   

Abstract

The present study examined the effects of the mGluR1 antagonist JNJ16259685 (JNJ) and the mGluR5 antagonist 2-methyl-6-phenylethynylpyridine (MPEP) alone and in combination with morphine in two acute pain models (hotplate, warm water tail-withdrawal), and a persistent, inflammatory pain model (capsaicin). In the hotplate and warm water tail-withdrawal procedures, JNJ and MPEP were ineffective when administered alone. In both procedures, JNJ potentiated morphine antinociception. In the hotplate procedure, MPEP potentiated morphine antinociception at the highest dose examined, whereas in the warm water tail-withdrawal procedure MPEP attenuated morphine antinociception at a moderate dose and potentiated morphine antinociception at a high dose. For both JNJ and MPEP, the magnitude of this morphine potentiation was considerably greater in the hotplate procedure. In the capsaicin procedure, the highest dose of MPEP produced intermediate levels of antihyperalgesia and also attenuated the effects of a dose of morphine that produced intermediate levels of antihyperalgesia. In contrast, JNJ had no effect when administered alone in the capsaicin procedure and did not alter morphine-induced antihyperalgesia. The present findings suggest that the effects produced by mGluR1 and mGluR5 antagonists alone and in combination with morphine can be differentiated in models of both acute and persistent pain.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21971021      PMCID: PMC3220419          DOI: 10.1097/FBP.0b013e32834d13a2

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  44 in total

1.  3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity.

Authors:  Nicholas D P Cosford; Lida Tehrani; Jeffrey Roppe; Edwin Schweiger; Nicholas D Smith; Jeffrey Anderson; Linda Bristow; Jesse Brodkin; Xiaohui Jiang; Ian McDonald; Sara Rao; Mark Washburn; Mark A Varney
Journal:  J Med Chem       Date:  2003-01-16       Impact factor: 7.446

2.  The competitive N-methyl-D-aspartate receptor antagonist (-)-6-phosphonomethyl-deca-hydroisoquinoline-3-carboxylic acid (LY235959) potentiates the antinociceptive effects of opioids that vary in efficacy at the mu-opioid receptor.

Authors:  Richard M Allen; Arthur L Granger; Linda A Dykstra
Journal:  J Pharmacol Exp Ther       Date:  2003-09-15       Impact factor: 4.030

3.  Up-regulation of metabotropic glutamate receptor subtypes 3 and 5 in spinal cord in a clinical model of persistent inflammation and hyperalgesia.

Authors:  Sharron Dolan; James G Kelly; Ana M Monteiro; Andrea M Nolan
Journal:  Pain       Date:  2003-12       Impact factor: 6.961

4.  Protein kinase C-mediated enhancement of NMDA currents by metabotropic glutamate receptors in Xenopus oocytes.

Authors:  S R Kelso; T E Nelson; J P Leonard
Journal:  J Physiol       Date:  1992-04       Impact factor: 5.182

5.  Neurokinin release produced by capsaicin acting on the central terminals and axons of primary afferents: relationship with N-methyl-D-aspartate and GABA(B) receptors.

Authors:  L-J Lao; B Song; J C G Marvizón
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

6.  Inhibitory effects of MPEP, an mGluR5 antagonist, and memantine, an N-methyl-D-aspartate receptor antagonist, on morphine antinociceptive tolerance in mice.

Authors:  Ewa Kozela; Andrzej Pilc; Piotr Popik
Journal:  Psychopharmacology (Berl)       Date:  2002-11-20       Impact factor: 4.530

7.  Intrathecal MK-801 and local nerve anesthesia synergistically reduce nociceptive behaviors in rats with experimental peripheral mononeuropathy.

Authors:  J Mao; D D Price; D J Mayer; J Lu; R L Hayes
Journal:  Brain Res       Date:  1992-04-03       Impact factor: 3.252

8.  Modulation of morphine analgesia by site-specific N-methyl-D-aspartate receptor antagonists: dependence on sex, site of antagonism, morphine dose, and time.

Authors:  Kumar V S Nemmani; Judith E Grisel; Jennifer R Stowe; Richard Smith-Carliss; Jeffrey S Mogil
Journal:  Pain       Date:  2004-06       Impact factor: 6.961

9.  Morphine conditioned reward is inhibited by MPEP, the mGluR5 antagonist.

Authors:  P Popik; M Wróbel
Journal:  Neuropharmacology       Date:  2002-12       Impact factor: 5.250

10.  Capsaicin-induced hyperalgesia and mu-opioid-induced antihyperalgesia in male and female Fischer 344 rats.

Authors:  Andrew C Barrett; Eric S Smith; Mitchell J Picker
Journal:  J Pharmacol Exp Ther       Date:  2003-09-03       Impact factor: 4.030

View more
  6 in total

1.  Sex Differences in Microglia Activity within the Periaqueductal Gray of the Rat: A Potential Mechanism Driving the Dimorphic Effects of Morphine.

Authors:  Hillary H Doyle; Lori N Eidson; David M Sinkiewicz; Anne Z Murphy
Journal:  J Neurosci       Date:  2017-02-20       Impact factor: 6.167

2.  Targeting MOR-mGluR5 heteromers reduces bone cancer pain by activating MOR and inhibiting mGluR5.

Authors:  Sarah S Shueb; Samuel J Erb; Mary M Lunzer; Rebecca Speltz; Catherine Harding-Rose; Eyup Akgün; Donald A Simone; Philip S Portoghese
Journal:  Neuropharmacology       Date:  2019-07-01       Impact factor: 5.250

3.  TailTimer: A device for automating data collection in the rodent tail immersion assay.

Authors:  Mallory E Udell; Jie Ni; Angel Garcia Martinez; Megan K Mulligan; Eva E Redei; Hao Chen
Journal:  PLoS One       Date:  2021-08-19       Impact factor: 3.240

4.  Emotional Impairment and Persistent Upregulation of mGlu5 Receptor following Morphine Abstinence: Implications of an mGlu5-MOPr Interaction.

Authors:  Panos Zanos; Polymnia Georgiou; Loreto Rojo Gonzalez; Susanna Hourani; Ying Chen; Ian Kitchen; Brigitte L Kieffer; Raphaelle Winsky-Sommerer; Alexis Bailey
Journal:  Int J Neuropsychopharmacol       Date:  2016-07-05       Impact factor: 5.176

5.  Bivalent ligand that activates mu opioid receptor and antagonizes mGluR5 receptor reduces neuropathic pain in mice.

Authors:  Cristina D Peterson; Kelley F Kitto; Eyup Akgün; Mary M Lunzer; Maureen S Riedl; Lucy Vulchanova; George L Wilcox; Philip S Portoghese; Carolyn A Fairbanks
Journal:  Pain       Date:  2017-12       Impact factor: 7.926

6.  Opposite effects of neuropeptide FF on central antinociception induced by endomorphin-1 and endomorphin-2 in mice.

Authors:  Zi-long Wang; Quan Fang; Zheng-lan Han; Jia-xin Pan; Xu-hui Li; Ning Li; Hong-hai Tang; Pei Wang; Ting Zheng; Xue-mei Chang; Rui Wang
Journal:  PLoS One       Date:  2014-08-04       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.